End‐Of‐Life Outcomes and Healthcare Utilization for Patients With Hepatocellular Carcinoma Who Received Immune Checkpoint Inhibition

ABSTRACT Introduction Immune checkpoint inhibitors (ICI) have revolutionized treatment for advanced hepatocellular carcinoma (HCC). However, end‐of‐life (EOL) outcomes and healthcare utilization patterns prior to death for patients who receive ICI compared to non‐ICI as their last therapy are unknow...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Margaret C. Wheless, Anna‐Carson R. Uhelski, Sarah K. Cimino, Henry J. Domenico, Sara F. Martin, Mohana B. Karlekar, Thatcher R. Heumann, Kristen K. Ciombor, Laura W. Goff, Rajiv Agarwal
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2025-10-01
Saila:	Cancer Medicine
Gaiak:	end‐of‐life goals of care hepatocellular carcinoma immune checkpoint inhibitors
Sarrera elektronikoa:	https://doi.org/10.1002/cam4.71293
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!